Although the molecular functions of the potential targets associated with omeprazole, lansoprazole, pantoprazole, and rabeprazole in osteoporosis exhibit heterogeneity, these targets are significantly enriched in the endocrine resistance and ErbB signaling pathways. This evidence concerns the gene EGFR and osteoporosis.